NCT06135584

Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

Prospective Cohort Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: The Affiliated Hospital of Hangzhou Normal University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis/cirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.

Conditions

• Metabolic Dysfunction-associated Fatty Liver Disease
• Cirrhosis

Interventions

Type	Name	Description
DRUG	Pioglitazone metformin tablets	Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
DRUG	Other drugs	Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
OTHER	Drug-free	Drug-free

Timeline

• Start date: 2023-11-18
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2023-11-18
• Last updated: 2023-11-18